Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$53.84 USD
+0.50 (0.94%)
Updated Jul 26, 2024 12:34 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Earnings News For CRNX
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
-
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
-
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
-
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates
-
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates
-
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
-
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates
-
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline
-
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates